Cue Biopharma, Inc. (CUE)

1,9150 +0,0050 (+0,26%) Alla chiusura: 04:00PM EDT

Cue Biopharma, Inc.

40 Guest Street
Boston, MA 02135
United States
617 949 2680
https://www.cuebiopharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 53

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel R. Passeri J.D., M.Sc.	CEO & Director	607,98k	N/D	1961
Dr. Anish Suri Ph.D.	President & Chief Scientific Officer	447,34k	N/D	1974
Ms. Kerri-Ann Millar	Chief Financial Officer	447,34k	N/D	1970
Dr. Ronald D. Seidel III, Ph.D.	Co-Founder	316,63k	N/D	1976
Dr. Rodolfo J. Chaparro	Co-Founder & Senior Advisor	316,63k	N/D	1973
Dr. Steven C. Almo	Co-Founder and Chairman of Scientific & Clinical Advisory Board	N/D	N/D	1961
Mr. Colin G. Sandercock J.D., MSE	Senior VP, General Counsel & Secretary	381,42k	N/D	1957
Dr. Matteo Levisetti M.D.	Chief Medical Officer	N/D	N/D	1969

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Cue Biopharma, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 7; diritti degli azionisti: 4; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.